|
Leveraging BCMA-Directed Therapies for Improved Patient Outcomes in Relapsed/Refractory Multiple Myeloma
STATEMENT OF NEED
Multiple myeloma is a disease that remains incurable for most patients, many of whom become refractory to the majority of available treatments (Kumar et al, 2022). It is estimated that 35,730 new cases of multiple myeloma are diagnosed in the United States annually, and 12,590 people die of the disease (Siegel et al, 2023). Agents targeting B-cell maturation antigen (BCMA), including antibody-drug conjugates (ADCs), chimeric antigen receptor (CAR) T-cell therapies, and bis... |
|
|
The Role of the Clinical Pharmacist in the Management of Multiple Myeloma
Multiple myeloma (MM) is the second most common hematologic malignancy in the United States and is characterized by monoclonal proliferation of malignant plasma cells that accumulate within the bone marrow. The incidence of MM has increased in recent years, in part due to the revised definition of symptomatic MM from the International Myeloma Working Group in 2014. The National Cancer Institute estimated a total of 34,470 new cases in 2022, with 12,640 deaths. Despite significant advancements ... |
|
|
Individualized Strategies for Relapsed/Refractory Multiple Myeloma: Navigating Complexity with BCMA-Targeted and Novel Bispecific Antibodies
The expanding armamentarium of therapies for R/R MM shifts therapy selection from an algorithmic approach to an individualized strategy that requires consideration of the nature of relapse, prior therapies, treatment-related toxicities, as well as patient comorbidities and preferences. With the introduction of novel bispecific antibodies, specialists must learn how to optimally sequence these therapies and manage adverse events. To help clinicians navigate this complexity, individualized educa... |
|
|
Addressing Key Questions About BCMA-Targeted Therapy for Relapsed/Refractory Multiple Myeloma
ACTIVITY DESCRIPTION
Though treatment advances have improved outcomes for most patients, MM remains an incurable disease characterized by continuous relapse. However, the treatment landscape for relapsed/refractory MM (RRMM) has expanded in recent years, and patients who relapse and/or become refractory to initial therapies are benefiting from the increasing availability of a diverse range of novel agents, including B-cell maturation antigen (BCMA)"targeted immunotherapies. These agents ... |
|
|
Across the Compendium: Practical Pathways to Integrate Bispecific Antibodies Into Care for Patients With Relapsed/Refractory Multiple Myeloma
As the armamentarium of therapies for relapsed/refractory multiple myeloma (R/R MM) expands, several factors, including previous therapy, treatment-related toxicity, and comorbidities must be considered as part of clinical decision making. To assist the multidisciplinary treatment team in these efforts, and ensure patients are receiving cutting-edge cancer care, this immersive digital practice guide highlights best practices, clinical pearls, and strategies to overcome pitfalls in the administ... |
|